The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Eosinophilic Granulomatosis With Polyangiitis Treatment Market Between 2026 And 2030?

The eosinophilic granulomatosis with polyangiitis treatment market has demonstrated robust expansion over recent years. It is projected to grow from $1.41 billion in 2025 to $1.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.8%. This market’s historical growth can be ascribed to factors such as increased awareness of autoimmune diseases, the ongoing dependence on corticosteroids, advancements in rare disease diagnosis, specialized hospital-based immunology care, and the requirements for effective inflammation management.

The eosinophilic granulomatosis with polyangiitis treatment market is anticipated to demonstrate substantial expansion over the next few years, projected to reach $2.22 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.6%. This expected growth during the forecast period can be credited to advancements in biologic drugs, financial support for rare diseases, personalized approaches to autoimmune treatment, the expansion of specialty clinics, and the adoption of early intervention protocols. Significant trends for the forecast period include an increasing reliance on targeted biologic therapies, a greater concentration on rare autoimmune conditions, the rise in long-term immunosuppressive treatments, the broadening of specialized autoimmune care, and a primary focus on initial disease control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23392&type=smp

What Key Drivers Are Influencing The Growth Of The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?

The increasing occurrence of asthma in the elderly demographic is anticipated to stimulate expansion within the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in the coming years. This respiratory ailment hinders breathing as it causes the lung’s air passages to swell and constrict. Its prevalence among older adults is rising, largely attributable to diminishing lung capabilities; as lungs lose flexibility and airway muscles weaken, respiration becomes more challenging, increasing susceptibility to inflammation and other respiratory issues in this group. Consequently, the growing number of asthma cases in seniors prompts greater screening for associated conditions like eosinophilic granulomatosis with polyangiitis, a disease that frequently originates with asthma, thereby boosting the need for its therapies. As an illustration, in 2024, the Global Initiative for Asthma, a US-based medical organization, reported asthma as a widespread chronic non-communicable illness affecting over 260 million people worldwide and leading to over 450,000 annual fatalities. Hence, the increasing occurrence of asthma within the elderly population is a key factor propelling the expansion of the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market.

Which Market Segments Are Examined In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market Study?

The eosinophilic granulomatosis with polyangiitis treatment market covered in this report is segmented –

1) By Drug Class: Steroids, Immunosuppressant, Biologics, Immune Globulins

2) By Route Of Administration: Oral, Intravenous, Intramuscular

3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Drug Stores, Retail Pharmacies

4) By End User: Hospitals, Clinics, Home Healthcare

Subsegments:

1) By Steroids: Glucocorticoids, Mineralocorticoids

2) By Immunosuppressants: Calcineurin Inhibitors, Antimetabolites, Alkylating Agents

3) By Biologics: Interleukin Inhibitors, Monoclonal Antibodies, TNF-alpha Inhibitors

4) By Immune Globulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

Which Market Trends Are Creating New Opportunities In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?

Leading firms within the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market are carrying out clinical investigations to evaluate the efficacy and safety of both novel and established treatments. The objective of these trials is to broaden therapeutic choices, obtain necessary regulatory clearances, and elevate the standard of patient care. For example, AstraZeneca, a UK-based pharmaceutical and biotechnology firm, revealed favorable outcomes from its MANDARA Phase III trial in September 2024. This study indicated that Fasenra (benralizumab) successfully induced remission in individuals suffering from eosinophilic granulomatosis with polyangiitis. The findings further highlighted that benralizumab achieved remission rates similar to mepolizumab, concurrently decreasing the requirement for oral glucocorticoids. Such progress signifies a notable stride towards more precise and steroid-reducing therapeutic strategies for eosinophilic granulomatosis with polyangiitis.

Who Are The Primary Competitors In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?

Major companies operating in the eosinophilic granulomatosis with polyangiitis treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Roche Holding AG, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Intas Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Biogen Inc., Fresenius Kabi, Amgen Inc., Sun Pharmaceutical Industries, Apotex Inc., Cipla Ltd., Dr. Reddy’s Laboratories, Lupin Limited, Alkem Laboratories, NS Pharma

Read the full eosinophilic granulomatosis with polyangiitis treatment market report here:

https://www.thebusinessresearchcompany.com/report/eosinophilic-granulomatosis-with-polyangiitis-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Eosinophilic Granulomatosis With Polyangiitis Treatment Market?

North America was the largest region in the eosinophilic granulomatosis with polyangiitis (EGPA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic granulomatosis with polyangiitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Eosinophilic Granulomatosis With Polyangiitis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23392&type=smp

Browse Through More Reports Similar to the Global Eosinophilic Granulomatosis With Polyangiitis Treatment Market 2026, By The Business Research Company

Anti Asthmatics And Copd Drugs Market

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Allergic Rhinitis Global Market Report

https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model